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The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the
focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA
approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/
PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1,
expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to
enhanced antitumor CD8+ T cell responses and tumor regression. The influence of PD-L1
expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the
impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8+
T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker
in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor
cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade
therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to
antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the
context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well
as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8+ T cell responses.
Keywords: immunotherapy, programmed death-1:programmed death-ligand 1 blockade, B7-H1 (programmed
death-ligand 1), T cells, CTL, tumor

INTRODUCTION
Programmed death-ligand 1 (PD-L1, also referred to as B7-H1 or CD274) is constitutively expressed by
cells of the myeloid lineage, including macrophages and dendritic cells (1–3). Cells from the lymphoid,
endothelial, and epithelial lineages, including cancer cells from these lineages, express PD-L1 upon activation by IFN-γ and TNF-α (4). Naïve murine T cells express low levels of PD-L1, while naïve human T cells
do not; however, both murine and human T cells express high levels of PD-L1 upon antigen stimulation
(3, 5). PD-L1 has been extensively characterized as a ligand for PD-1, an inhibitory receptor expressed by
activated CD8+ T cells. Upon interaction with PD-L1, PD-1 counteracts signaling downstream of T cell
receptor (TCR) ligation and CD28 co-stimulation (6). When PD-L1 interacts with PD-1, the immunoreceptor tyrosine-based inhibitory motifs and immunoreceptor tyrosine-based switch motifs on the
Abbreviations: APC, antigen-presenting cells; B7-H1, B7 homolog 1; Bim, Bcl-2-like protein 11; HCV, hepatitis C virus; HIF1α, hypoxia-inducible factor-1α; LCMV, lymphocytic choriomeningitis virus; MDC, myeloid dendritic cells; MDSC, myeloidderived suppressor cell; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; sPD-L1, soluble PD-L1.
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intracellular domain of PD-1 become phosphorylated. This
recruits the phosphatases SHP-1 and SHP-2 to the intracellular
domain of PD-1, which is in the vicinity of the TCR. SHP-1 and
SHP-2 dephosphorylate the immunoreceptor tyrosine-based
activation motifs of the TCR, thus dampening the signaling
downstream of the TCR (7). By inhibiting TCR signaling, PD-1
prevents the activation of the PI3K/Akt and c-Myc pathways, and
inhibits cell survival, proliferation, and cytokine production by
CD8+ T cells (8). It is important to note that PD-L1 also interacts
with CD80 (B7-1), which is expressed on the surface of CD8+
T cells. The signaling events that are initiated downstream of
CD80 are still under investigation, but have been shown to have
similar effects on CD8+ T cell function as signaling downstream
of the PD-L1/PD-1 interaction (9–11).
The rationale for PD-L1/PD-1 checkpoint blockade therapies
is to block the PD-L1/PD-1 interaction between tumor cells
and CD8+ T cells with an antibody to allow for CD8+ T cells to
overcome PD-1 inhibitory signaling and eliminate the tumor cells.
FDA-approved anti-PD-1 antibodies include pembrolizumab and
nivolumab. Currently pembrolizumab is approved for treatment
of metastatic melanoma, both squamous and non-squamous nonsmall cell lung cancer (NSCLC), head and neck squamous-cell
carcinoma, and Hodgkin’s lymphoma, and nivolumab is approved
for treatment of metastatic melanoma, both squamous and nonsquamous NSCLC, and renal-cell carcinoma. FDA-approved
anti-PD-L1 antibodies include durvalumab, atezolimuab, and
avelumab. Currently, durvalumab is approved for treatment of
urothelial carcinoma, atezolimuab is approved for treatment of
NSCLC and urothelial carcinoma, and avelumab is approved
for treatment of Merkel cell carcinoma. PD-L1/PD-1 checkpoint
blockade treatments yield durable responses for a significant number of patients, but many patients exhibit variable responses or no
response to the treatments (12–24). These drugs are all in ongoing
clinical trials to determine their use for additional tumor types.
There are also efforts underway to identify biomarkers that can
be used to predict which patients will likely respond to PD-L1/
PD-1 checkpoint blockade therapies. Logically, the expression of
PD-L1 by a patient’s tumor cells is the focus of much of these
efforts and will be discussed below. Numerous other biomarkers
have been identified as useful tools for distinguishing “nonresponders” from “responders” for PD-L1/PD-1 checkpoint
blockade therapy. The presence of circulating PD-1+ CD8+ T cells
that express the pro-apoptotic molecule Bim was predictive of
clinical benefit in patients with metastatic melanoma that were
treated with anti-PD-1 checkpoint blockade therapy (25). When
PD-1+ CD8+ T cells interact with PD-L1, the expression of Bim
is increased (11), therefore Bim expression by circulating PD-1+
CD8+ T cells is associated with CD8+ T cells that have encountered
PD-L1 and would be reinvigorated by PD-L1/PD-1 checkpoint
blockade. PD-1+ CD8+ T cells that are reinvigorated by PD-L1/
PD-1 checkpoint blockade depend on CD28 co-stimulation
for proliferation, thus the expression of CD28 by circulating
PD-1+ CD8+ T cells has also been identified as a potential
biomarker for predicting responses to PD-L1/PD-1 checkpoint
blockade therapy (26). PD-L1 is classically characterized as
membrane-bound, but a soluble form of PD-L1 (sPD-L1) also
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exists and high serum levels of sPD-L1 are associated with poor
prognosis in renal-cell carcinoma and multiple myeloma (27, 28).
Increased levels of sPD-L1 in the circulation of patients treated
with PD-L1/PD-1 checkpoint blockade for malignant melanoma
predicted a greater chance of partial response to therapy when
assayed at 5 months after initiation of treatment (29). Tumors
with deficiency in the mismatch-repair pathway for DNA repair
or with high microsatellite instability are highly immunogenic
and patients with tumors having either of these characteristics
are more likely to respond to PD-L1/PD-1 checkpoint blockade
therapy (30). These types of tumors, regardless of tissue of origin,
generate multitudes of novel antigens due to their high mutation
burden, making them ideal targets for CD8+ T cell responses
reinvigorated by PD-L1/PD-1 checkpoint blockade therapy. The
FDA recently approved pembrolizumab as a treatment for any
unresectable or metastatic solid tumor that is mismatch repair
deficient or has high microsatellite instability. This is the first
FDA-approved treatment that is based on a biomarker rather
than on the tissue of origin of the tumor.
As mentioned earlier, PD-L1 expression by tumor cells has
been characterized as a biomarker for predicting patient outcomes to PD-L1/PD-1 checkpoint blockade therapy. Multiple
studies have shown that PD-L1 expression is predictive of
positive responses to PD-L1/PD-1 checkpoint blockade therapy
(31–33). However, patients with PD-L1 negative tumors often
exhibit positive responses to PD-L1/PD-1 checkpoint blockade
therapies (20). Despite these findings, the FDA has approved
PD-L1 biomarker tests as companions to nivolumab for treatment of NSCLC, pembrolizumab for treatment of NSCLC, and
atezolimuab for treatment of urothelial carcinoma. Some of the
unpredictability of responses to PD-L1/PD-1 checkpoint blockade therapies may be due to the heterogeneity and dynamics of
PD-L1 expression by tumor cells and immune cells, including
dendritic cells and CD8+ T cells (34, 35). Recent reports indicate
that PD-L1 expressed by both tumor cells and non-tumor host
cells contributes to the efficacy of PD-L1/PD-1 checkpoint
blockade therapies in preclinical models (36, 37). It is essential
to consider the role of the PD-L1/PD-1 interaction outside of the
tumor setting in order to gain a better understand of the effects
of PD-L1/PD-1 checkpoint blockade therapies.
The PD-L1/PD-1 interaction is involved during the initial
activation or priming phase of naïve CD8+ T cells as PD-L1
is expressed on the surface of dendritic cells in the spleen and
lymph nodes where T cell priming takes place, and PD-1 expression by CD8+ T cells is upregulated early on during the priming
phase (38–40). In this review, we will consider how PD-L1/
PD-1 checkpoint blockade therapies affect the priming phase of
antitumor CD8+ T cell responses. Activated CD8+ T cells also
express PD-L1, and it has been demonstrated that this expression of PD-L1 plays a role in the survival of activated CD8+
T cells during the contraction phase of an immune response
(41, 42). Accordingly, the CD8+ T cell intrinsic role for PD-L1/
PD-1 signaling will also be examined. Finally, the role of PD-L1
expressed by tumor cells in regulating CD8+ T cell antitumor
immune responses will be considered. These interactions are
summarized in Figure 1.
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various toll-like receptor ligands (40). In considering how PD-L1/
PD-1 checkpoint blockade therapies influence antitumor CD8+
T cell responses, it is important to first consider the role of PD-L1
during the priming phase of an immune response. During this
phase, naïve CD8+ T cells that are reactive against tumor antigens
get activated in secondary lymphoid organs and undergo important changes in differentiation that will affect the resulting effector
and memory antitumor CD8+ T cell responses. Several studies
have demonstrated that PD-L1 signaling during the priming
phase limits CD8+ T cell responses, so PD-L1/PD-1 checkpoint
blockade therapies likely work in part by enhancing CD8+ T cell
responses by influencing events during the priming phase of an
antitumor immune response.
In order to generate an effective antitumor CD8+ T cell response,
the signals provided by dendritic cells during the priming phase
must initiate rapid proliferation of antitumor CD8+ T cells as
well as orchestrate differentiation programs that will give rise to
effector CD8+ T cells and memory CD8+ T cells. Several groups
have independently demonstrated that CD8+ T cells exhibit
increased proliferation when primed in the absence of PD-L1
signaling, indicating that PD-L1 signaling serves to restrict the
proliferative capacity of CD8+ T cells during activation. Benedict
et al. demonstrated that dendritic cells infected with CMV had
high surface expression of PD-L1 and were unable to induce proliferation of antigen-specific CD8+ T cells. Including an antibody
against PD-L1 in their in vitro priming model largely restored the
ability of CMV-infected dendritic cells to induce proliferation of
antigen-specific CD8+ T cells (46). In an in vivo priming model,
we found that the numbers of antigen-specific CD8+ T cells
significantly increased in animals immunized with activated
dendritic cells that lacked PD-L1 expression as compared to activated dendritic cells with intact PD-L1 expression (40). Using an
HSV-1 model, Channappanavar et al. demonstrated that systemic
delivery of anti-PD-L1 antibody 1 day prior to HSV-1 infections
allowed for increased proliferation of antigen-specific CD8+
T cells as compared to mice infected with HSV-1 in the absence
of anti-PD-L1 treatment (47). Together these studies indicate
that systemic treatment with PD-L1/PD-1 checkpoint blockade
antibody therapy should result in increased proliferation of CD8+
T cell responses being primed in patients.
Differentiation of effector and memory CD8+ T cells occurs
during the priming phase through a mechanism termed programming, in which naïve CD8+ T cells respond to external stimuli,
including TCR signaling, co-stimulatory signaling, and cytokine
signaling (38). The combination of these stimuli that a naïve
CD8+ T cell encounters will determine the outcome of programming and have long-lasting impacts on the resulting effector and
memory populations (48). In order to generate a potent effector
and memory CD8+ T cell responses, naïve CD8+ T cells must
encounter a cognate TCR stimulus in the context of positive costimulatory signals and pro-inflammatory cytokines (49). It has
been well established that PD-L1 signaling is integrated during
CD8+ T cell priming to restrain the differentiation of effector and
memory CD8+ T cells.
Effector CD8+ T cells primed in the absence of PD-L1 signaling
exhibit increased cytokine production and enhanced cytotoxic
activity as compared to CD8+ T cells primed in the presence

Figure 1 | The programmed death ligand-1 (PD-L1) (B7-H1) pathway in
regulation of T cell responses to tumors. Once naïve T cells encounter
cognate antigen presented by antigen-presenting cells (APC), they are
primed and express PD-1 and CD80, two receptors of PD-L1. PD-1 once
engaged by its ligand recruits the phosphatase SHP-2 to inhibit AKT
activation by preventing CD28-mediated activation of PI3K. Along with CD80,
PD-1 suppresses T cell expansion, and limits differentiation to memory cells
by upregulation of Bim. Following expansion, T cells undergo contraction in
which PD-L1 expressed by activated T cells provides pro-survival signals to
T cells by upregulating Bcl-xl and inhibiting p38 MAPK activation. After
arriving at the tumor site, PD-L1 expressed by tumor cells or tumorassociated macrophages or MDSCs suppresses the function of tumorreactive T cells by inducing either apoptosis or exhaustion. MDSC,
myeloid-derived suppressor cells; Bim, Bcl-2-like protein 11.

THE ROLE OF PD-L1 EXPRESSED BY
DENDRITIC CELLS
Both PD-1 and CD80 are expressed on CD8+ T cells early during
activation and priming by dendritic cells (43–45). Additionally,
dendritic cells express cell-surface PD-L1 upon activation by
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of PD-L1 signaling (40, 44, 45, 47, 50). Immunization of mice
with PD-L1 deficient dendritic cells pulsed with OVA peptide
resulted in effector CD8+ T cells that secreted increased levels of
IFN-γ and were better able to control B16-OVA tumor growth as
compared to effector CD8+ T cells primed by dendritic cells with
intact PD-L1 expression (40). Similar results were found when
anti-PD-L1 antibody was used to block PD-L1 signaling by the
injected dendritic cells in this same study. CD8+ T cells activated
in the absence of PD-L1 signaling had significantly increased
production of IFN-γ (50). Using an HSV-1 infection model,
Channappanavar et al. showed that blocking PD-L1 signaling
during the priming phase resulted in effector CD8+ T cells with
increased granzyme B exocytosis upon ex vivo antigen stimulation. Mice injected with anti-PD-L1 prior to HSV-1 infection also
demonstrated significantly lower viral load 6 days postinfection
(47). Using a brief in vitro priming model to activate OT-I CD8+
T cells with OVA-presenting dendritic cells with either intact
or deficient PD-L1 expression, it was demonstrated that CD8+
T cells primed in the absence of PD-L1 secreted increased levels
of IFN-γ and exhibited increased in vivo cytotoxic activity (45).
These studies show that PD-L1 signaling during the priming
phase influences the differentiation of effector CD8+ T cells by
restraining the acquisition of effector functions.
During the priming phase, PD-L1 also controls differentiation
of the resulting population of memory CD8+ T cells (51). In the
same HSV-1 infection model as described above, Channappanavar
et al. investigated the influence of PD-L1 signaling during
priming on the resulting antigen-specific CD8+ T cell memory
population. PD-L1 blocking antibody or isotype control antibody
was injected 1 day prior and 3 days after HSV-1 infection. Mice
were re-challenged with HSV-1 32 days after infection and CD8+
T cell recall responses were assayed on day 4 after re-infection. In
mice that primed an anti-HSV-1 CD8+ memory T cell response
in the absence of PD-L1 signaling, the memory recall response
exhibited increased antigen-specific secretion of IFN-γ and
granzyme B (47). Similar data were generated using an in vivo
priming model and B16-OVA tumor challenge in which wildtype mice were injected with naïve OT-I CD8+ T cells (CD45.2+)
and OVA-presenting activated bone marrow-derived dendritic
cells that were either wild type or PD-L1 deficient. On day 30 after
the injection of the naïve CD8+ T cells and activated dendritic
cells, the mice were challenged with an intravenous injection of
B16-OVA tumor cells. The recall response of the CD45.2+ T cells
was analyzed 4 days after tumor challenge. In mice that had
PD-L1-deficient dendritic cells during the priming phase, there
was an increase in IFN-γ in the lungs as compared to mice that
received dendritic cells with intact PD-L1 (45). Together these
studies demonstrate that PD-L1 signaling is integrated during the
priming phase and limits the differentiation of memory CD8+
T cell populations.
An additional level of regulation during T cell priming is
ligand-induced TCR down-modulation, in which TCRs that
have engaged with cognate peptide–MHC are internalized and
downstream signaling is terminated (52, 53). Karwacz et al. investigated the influence of PD-L1/PD-1 signaling on the process of
TCR down-modulation during priming. They knocked-down
PD-L1 expression in bone marrow-derived dendritic cells using
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lentivirus-delivered short hairpin RNA and found that in the
absence of PD-L1 signaling during the priming phase (both
in vitro and in vivo) CD8+ T cells exhibited decreased TCR
down-modulation as compared to CD8+ T cells primed by bone
marrow-derived dendritic cells with PD-L1 expression intact (50).
They went on to show that when PD-L1 is absent during priming,
CD8+ T cells failed to upregulate the E3 ubiquitin ligase Cbl-b,
which has been demonstrated to contribute to ligand-induced
TCR down-modulation (54–56). These results were replicated
when antibodies blocking either PD-L1 or PD-1 were included
in their in vitro priming model, thus implicating a role for PD-L1
signaling in TCR down-modulation. In addition to membrane
expression of PD-L1 by dendritic cells, a sPD-L1 produced by
activated human dendritic cells may provide a non-proximal
regulation of circulating PD-1+ or CD80+ T cells by dendritic cells
(57). Altogether these studies indicate that blockade of PD-L1
signaling during the priming phase of CD8+ T cells would be
beneficial for priming antitumor immune responses.

THE ROLE OF PD-L1 EXPRESSED BY
EFFECTOR CD8+ T CELLS
CD8+ T cells upregulate expression of PD-L1 upon antigen stimulation, so it is important to consider how PD-L1/PD-1 checkpoint
blockade therapies influence effector CD8+ T cells. Several studies
have reported a T cell intrinsic pro-survival/antiapoptotic role for
PD-L1 expressed by effector CD8+ T cells; therefore, it is likely
that PD-L1/PD-1 checkpoint blockade therapies have deleterious effects on the functions of effector CD8+ T cells. Since the
goal of PD-L1/PD-1 checkpoint blockade therapies is to enhance
CD8+ T cell killing of tumor cells, it is essential that we more fully
understand the role of PD-L1 expressed by effector CD8+ T cells.
Using an OVA protein immunization model of antigen stimulation in mice, Pulko et al. demonstrated that PD-L1 expressed
by effector CD8+ T cells is required for their survival during the
contraction phase of an immune response (41). Six days following
immunization with OVA protein and poly(I:C), PD-L1-deficient
CD8+ T cells exhibited increased contraction and enhanced
susceptibility to being killed by other CD8+ T cells. Additionally,
upon in vitro antigen stimulation, PD-L1-deficient CD8+ T cells
expressed lower levels of Bcl-xL, an antiapoptotic molecule. Saha
et al. demonstrated similar findings in a mouse graft-versus-host
disease model (58). PD-L1-deficient allogeneic donor CD8+
T cells exhibited decreased expansion and survival 5 days after
transfer as compared to wild-type allogeneic donor CD8+ T cells.
The impaired survival of PD-L1-deficient CD8+ T cells was determined to be due to lower expression levels of the pro-survival
proteins Bcl-xL and CD127. Additionally, PD-L1-deficient allogeneic donor CD8+ T cells had diminished cytokine production
and impaired metabolic activity, including decreased glycolytic
capability, decreased oxidative phosphorylation, and decreased
fatty acid oxidation as compared to wild-type allogeneic donor
CD8+ T cells. Another report confirmed the decreased expression of Bcl-xL in PD-L1-deficient CD8+ T cells and proposed
that the interaction of PD-L1 with CD80, both expressed by
CD8+ T cells, contributes to CD8+ T cell survival and expansion
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(59). This pro-survival/antiapoptotic role for PD-L1 expressed
by CD8+ T cells could explain the deleterious effects of PD-L1
blockade as reported in Listeria monocytogenes infection models
(60–62) and could also explain the variable patient responses to
PD-L1/PD-1 checkpoint blockade therapy. The role of PD-L1
expressed by CD8+ T cells within a tumor setting needs to be
further elucidated. It was recently demonstrated that certain antiPD-L1 blocking antibodies are capable of inducing apoptosis of
effector PD-L1+ CD8+ T cells through activating the p38 MAPK
pathway, and are thus ineffective as tumor treatments (42). Since
this potential agonist effect of anti-mouse PD-L1 antibody was
observed in preclinical models, whether therapeutic antibodies to
human PD-L1 would have similar agonist effects warrants further
investigation.

also produce a sPD-L1 that can be detected in the plasma of
cancer patients and suppresses T cell functions (27). Recently,
the increase of sPD-L1 in melanoma patients has been proposed
as a potential mechanism of resistance to immune checkpoint
blockade therapy (29, 81).
In addition to restraining effector functions in CD8+ T cells,
PD-L1 signaling also induces apoptosis of effector CD8+ T cells (2,
70, 73). Signaling downstream of PD-1 has been shown to inhibit
the CD28-mediated upregulation of the pro-survival molecule
Bcl-xL (8). HIV-specific CD8+ T cells have been shown to express
decreased levels of Bcl-xL and exhibit increased susceptibility to
apoptosis that is correlated to increased levels of PD-1 surface
expression (73, 82). PD-L1 co-stimulation induced increased
expression of the pro-apoptotic molecule Bim by effector CD8+
T cells in an in vitro model (11). Accordingly, PD-L1 co-stimulation
failed to induce apoptosis in Bim-deficient effector CD8+ T cells.
Larrubia et al. also reported increased Bim expression levels in
CD8+ T cells with high PD-1 expression levels in patients with
chronic HCV infection (83). Additionally, PD-1+ CD8+ T cells
isolated from B16 tumors in mice express higher levels of Bim as
compared to PD-1− CD8+ T cells isolated from the same tumor
(84). This same trend was observed in peripheral-blood tumorreactive CD8+ T cells from melanoma patients. Through in vitro
PD-L1/PD-1 blockade studies, Dronca et al. demonstrated that
the anti-PD-1 antibodies currently used clinically (nivolumab and
pembrolizumab) decrease Bim expression levels in human PD-1+
CD8+ T cells in patients who respond to treatment. Importantly,
it was demonstrated that PD-L1 induced increased expression of
Bim by signaling through both PD-1 and CD80. If the interaction
between either PD-L1 and PD-1 or PD-L1 and CD80 was blocked
using antibodies, then the PD-L1-induced increase in Bim levels
was lost (11). Related to this, it was found that CD80-deficient
CD8+ exhibited an enhanced memory response to immunization
as compared to wild-type CD8+ T cells that were co-transferred
into a naïve host, again indicating that PD-L1 signaling through
CD80 on CD8+ T cells restrains the memory response (11).
Blockade of PD-L1 may also blunt pro-survival signal of PD-L1 to
tumor cells per se since it has been reported that reverse signaling
of PD-L1 promotes tumor survival and growth (85, 86).
Effector CD8+ T cells require a massive amount of energy to
maintain rapid proliferation and effector functions. Naïve CD8+
T cells utilize oxidative phosphorylation, but upon activation
CD8+ T cells make a metabolic switch and primarily rely upon
the less efficient metabolic program of glycolysis (87, 88). Since
glycolysis is less efficient (there are two ATP molecules produced per molecule of glucose used in glycolysis versus 36 ATP
molecules produced per molecule of glucose used in oxidative
phosphorylation) activated CD8+ T cells depend upon very high
rates of glycolysis to meet their energy demands and thus require
large amounts of glucose to be available in their surrounding
environment. Signaling downstream of CD28 co-stimulation
activates PI3K/Akt signaling, leading to increased expression of
genes necessary for the high glycolytic rate required by activated
CD8+ T cells (89). The influence of the tumor microenvironment, which is glucose deficient due to the rapid proliferation
and energy demands of tumor cells, on metabolism of antitumor
effector CD8+ T cells has been the focus of numerous recent

THE ROLE OF PD-L1 EXPRESSED BY
TUMOR CELLS AND TUMORASSOCIATED SUPPRESSOR CELLS
Effector CD8+ T cells primed against tumor antigens have the
potential to eliminate tumor cells, but have failed to do so in
patients with clinically diagnosed cancer. The tumor microenvironment is inhospitable to effector CD8+ T cells with numerous
overlapping mechanisms in place to inhibit CD8+ T cell responses,
including the cell-surface expression of PD-L1 by many tumor
types (63). Some tumor cells intrinsically express cell-surface
PD-L1 while other tumor cells express PD-L1 in response to
inflammatory cytokines, a mechanism termed adaptive resistance (64). If a tumor cell that expresses PD-L1 on its surface
encounters antitumor CD8+ effector T cells that expresses PD-1
or CD80, then the tumor cell will initiate signaling downstream
of PD-1 and CD80. Here, we will discuss the outcomes of this
encounter.
Effector CD8+ T cells isolated from tumor microenvironments
exhibit an exhausted phenotype characterized by high surface
expression of PD-1 and impaired responses to antigenic stimuli
(65–68). It has recently been determined that PD-1 signaling
does not initiate differentiation of the exhausted phenotype in
CD8+ T cells (69), but PD-1 signaling is widely accepted to be the
most important receptor involved in maintaining the exhausted
phenotype (70). Most of the studies regarding PD-L1/PD-1
signaling in CD8+ T cell exhaustion have been done using models of chronic viral infection, but these findings are applicable
to tumor settings. Blocking PD-1 signaling has been shown in
several models of chronic viral infections to restore antigenic
sensitivity of exhausted CD8+ T cells. Barber et al. infected mice
with lymphocytic choriomeningitis virus clone 13 then treated
mice with anti-PD-L1 antibody 23–37 days postinfection. They
found significantly decreased viral loads in mice treated with
anti-PD-L1 and increased levels of IFN-γ production by CD8+
T cells in response to viral antigen stimulation (71). These results
were quickly corroborated in HIV, Hepatitis C virus (HCV), and
Hepatitis B virus infections (72–78). Blocking PD-L1 signaling
in mouse tumor models has also been shown to restore effector
antitumor CD8+ T cell responses leading to tumor regression
and durable antitumor protection (40, 79, 80). Tumor cells
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studies. Here, we will discuss the influence of PD-L1 signaling on
the metabolism of antitumor effector CD8+ T cells.
It has long been appreciated that signaling downstream
of PD-1 ligation by PD-L1 leads to impaired glycolysis due to
PD-1-mediated inhibition of CD28 signaling (8). In a graftversus-host disease model, Saha et al. demonstrated that wildtype donor T cells in syngeneic PD-L1-deficient hosts exhibited
increased rates of glycolysis, indicating that PD-L1 signaling
serves to inhibit glycolysis downstream of PI3K/Akt signaling
(90). Among the necessary genes for glycolysis is the glucose
transporter, Glut1, expressed at very high levels on the surface
of activated CD8+ T cells (91). Syngeneic CD8+ T cells in PD-L1
deficient hosts exhibit significantly increased levels of Glut1
expression on the cell surface (90). Tumor microenvironments,
in addition to having limited glucose, often have high levels of
PD-L1 expression, both of which impair glycolysis in effector
CD8+ T cells (92). In a mouse model of solid tumors, when
PD-L1/PD-1 signaling was blocked, intratumoral CD8+ T cells
regained their ability to perform glycolysis and effector functions, which led to tumor regression (93). These data indicate
that PD-L1/PD-1 checkpoint blockade therapies, in addition to
lifting inhibition of effector function of antitumor CD8+ T cells,
additionally contribute to the regaining of metabolic fitness by
antitumor CD8+ T cells.
In addition to the priming phase of T cell responses, antigenpresenting cells regulate effector T cell function at peripheral
tissues, including inside tumors. Blood monocyte-derived
myeloid dendritic cells have cell-surface PD-L1, the expression
of which is increased by the hypoxic tumor microenvironment
(94). Hypoxia-inducible factor-1α caused a rapid, dramatic, and
selective upregulation of PD-L1 on splenic myeloid-derived
suppressor cells (MDSCs) along with macrophages, dendritic
cells, and tumor cells (95). Among the subsets of MDSC, it seems
monocytic-MDSCs (CD14+HLA-DRlow) express higher PD-L1
than other subsets in patients with the diffuse large B-cell lymphoma (96). PD-L1 expressed by tumor-associated MDSCs and
macrophages provides an immunosuppressive environment that
fosters cancer progression, and blockade of PD-L1 restored the
function of tumor-reactive T cells (97). Accordingly, a combination of checkpoint blockade therapy with reagents that inactivate
MDSCs is effective in overcoming resistance to checkpoint
blockade therapy (98). PD-1 is expressed by tumor-associated
macrophages, and signaling downstream of the PD-L1/PD-1
interaction inhibits phagocytosis, a crucial step in innate immunity to cancer (99). PD-1 expressed by monocytes induces IL-10
production and impairs T cell activation (100). It is possible
that the co-expression of PD-1 and PD-L1 by macrophages and

monocytes may form a regulatory circuit across innate and adaptive immune cells.

CONCLUDING REMARKS
Programmed death-ligand 1/PD-1 checkpoint blockade therapies are becoming an increasingly common treatment option
for patients with a variety of tumors. As their use becomes
more widespread, it continues to be important that we fully
understand the mechanism of action of therapeutic antibodies
and their target molecules, as well as develop reliable methods
to identify patients most likely to benefit from PD-L1/PD-1
checkpoint blockade therapies. When the interaction between
PD-L1+ tumor cells and PD-1+ CD8+ T cells, the intended target
for PD-L1/PD-1 checkpoint blockade therapies, is disrupted, the
result is reinvigoration of the antitumor CD8+ T cell response
and enhanced CD8+ T cell-mediated killing of tumor cells. As
interactions between PD-L1 and PD-1 are not limited to the
tumor microenvironment, it is important to consider the influence of the PD-L1/PD-1 interaction that occurs in other contexts.
Based on the findings reviewed here, it can be concluded that
PD-L1/PD-1 checkpoint blockade therapies likely enhance the
priming of antitumor CD8+ T cells, but may limit the survival
of antitumor CD8+ T cells by interfering with a CD8+ T cell
intrinsic pro-survival/antiapoptotic role for PD-L1 signaling.
This context-dependent role for the PD-L1/PD-1 interaction may
be responsible in part for the unpredictable patient responses to
PD-L1/PD-1 checkpoint blockade therapies.
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